Lyra Therapeutics (OTCMKTS:LYRA – Get Free Report) and Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
Valuation and Earnings
This table compares Lyra Therapeutics and Gyre Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyra Therapeutics | $400,000.00 | 0.89 | -$28.92 million | ($19.15) | -0.01 |
| Gyre Therapeutics | $116.59 million | 7.08 | $5.03 million | ($0.21) | -35.24 |
Insider & Institutional Ownership
95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Lyra Therapeutics and Gyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyra Therapeutics | -7,266.08% | N/A | -59.82% |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Lyra Therapeutics and Gyre Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyra Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Gyre Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
Gyre Therapeutics has a consensus price target of $16.00, suggesting a potential upside of 116.22%. Given Gyre Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Lyra Therapeutics.
Risk & Volatility
Lyra Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.
Summary
Gyre Therapeutics beats Lyra Therapeutics on 11 of the 14 factors compared between the two stocks.
About Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
